6 Dimensions Capital led a round for the miniprotein drug developer that included Nan Fung, GV and WuXi AppTec Corporate Ventures.
US-based miniprotein developer FogPharma completed a $66m series B round on Wednesday featuring property developer Nan Fung Group, internet technology conglomerate Alphabet and pharmaceutical firm WuXi AppTec.
6 Dimensions Capital, the healthcare fund formed by WuXi AppTec and VC firm Frontline BioVentures, led the round, which also included Blue Pool Capital, Horizons Ventures, Leerink Partners, Deerfield Management, Boyu Capital and unnamed non-institutional investors.
Alphabet and WuXi AppTec participated directly through respective subsidiaries GV and WuXi AppTec Corporate Ventures.
Founded in…